JS207 + 9MW2821

JS207 + 9MW2821 is an investigational **combination therapy** under clinical evaluation for the treatment of advanced cancers, notably triple-negative breast cancer. - **JS207** is a monoclonal antibody, though detailed public information on its exact target and mechanism is limited. - **9MW2821** is a novel antibody-drug conjugate (ADC) targeting **Nectin-4**, developed by Mabwell, designed for anti-tumor activity through selective delivery of cytotoxic payload to Nectin-4–expressing tumor cells[4][2][8]. This combination is being studied primarily in solid tumors, including triple-negative breast cancer, and trials are led by companies including Shanghai Junshi Biosciences and Mabwell[1][3][5][6].